Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
Bradley R CorrMarisa R MoroneyJeanelle SheederS Gail EckhardtBrandon SawyerKian BehbakhtJennifer R DiamondPublished in: Cancer (2020)
In the current single-institution series, patients with heavily pretreated ovarian cancer who were treated on phase 1 clinical trials experienced a median overall survival of 11.3 months. When available, phase 1 clinical trials represent a reasonable treatment option for patients with heavily pretreated ovarian cancer with a preserved performance status.